In this immunological ancillary study of the PREVAC trial, the authors show that approved Ebola virus vaccines induce memory T-cell responses that persist during the five year follow-up after initial vaccination.
- Aurélie Wiedemann
- Edouard Lhomme
- Huanying Zhou
